A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Abstract Text:

D Scott McMeekin,Michael W Sill,Doris Benbrook,Kathleen M Darcy,Deborah J Stearns-Kurosawa,Lynne Eaton,S Diane Yamada, ,

OBJECTIVES: A phase II trial was conducted to evaluate the anti-tumor activity and adverse effects of thalidomide in persistent or recurrent endometrial cancer refractory to cytotoxic chemotherapy and to correlate angiogenesis biomarker expression with clinical outcome. METHODS: Consenting patients were treated until progression or intolerable toxicity with an oral starting dose of 200 mg thalidomide/day that was to increase by 200 mg every 2 weeks to a target dose of 1000 mg/day. Vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF), and soluble endothelial protein C receptor (sEPCR) were analyzed by ELISA in pre and post-treatment specimens. RESULTS: Twenty-four of twenty-seven patients enrolled in the study were eligible, of whom 2 reached the target dose, 8 progressed before achieving the target dose, and 14 refused or had toxicity that prohibited escalation. Two patients (8.3%) remained progression-free>or=6 months. There were 3 (12.5%) with partial responses, 2 (8.3%) with stable disease, 15 (62.5%) with increasing disease, and 4 (16.7%) who were inevaluable for response. Median progression-free survival and overall survival were 1.7 months and 6.3 months, respectively. No grade 4 toxicities were observed. Common grade 3 toxicities included hematologic (n=3), cardiovascular (n=3), constitutional (n=3), and neurologic (n=4). Thalidomide did not decrease VEGF or bFGF levels but reduced sEPCR levels in serum. Elevated plasma vascular endothelial growth factor levels were associated with increased risk of progression and death. CONCLUSIONS: Thalidomide demonstrated limited ability to delay progression (as measured by PFS at 6 months), produce objective responses, or reduce angiogenic marker levels in chemotherapy refractory endometrial cancer. VEGF level appears to be prognostically significant in such patients, independent of thalidomide treatment.

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Publishing Authors By Initials

DS McMeekin,MW Sill,D Benbrook,KM Darcy,DJ Stearns-Kurosawa,L Eaton,SD Yamada, ,

For similar peptides: intercellular signaling peptides and proteins: angiogenic proteins: vascular endothelial growth factors: vascular endothelial growth factor a research abstracts see: peptides: intercellular signaling peptides and proteins: angiogenic proteins: vascular endothelial growth factors: vascular endothelial growth factor a research

PUBMED ID PMID:

MEDLINE DATE:

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Gynecologic oncology

VOLUME: 105

Page Numbers: 508-16

Journal Abbreviation:

ISSN: 0090-8258

DAY: 15

MONTH: 02

YEAR: 2007

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 365304

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Keywords Mesh Terms:

KEYWORDS: Vascular Endothelial Growth Factor A

MESH TERMS: blood

Chemical & Substance for Abstract: A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Information

Substance Name: Thalidomide

Registry Number: 50-35-1

Grant and Affiliation Information for A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

AFFILIATION: Department of Gynecologic Oncology, Health Sciences Center, OB/GYN, P.O. Box 26901, Williams Pavilion-Room WP2470, Oklahoma City, OK 73190, USA. scott-mcmeekin@ouhsc.edu

Country: United States

AGENCY: United States NCI

GRANT: CA 37517

ACRONYM: CA

MEDLINETA: Gynecol Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study Related Publications

• A classification method of hand movements using multi channel electrode.
• A method for measurement of water temperature in micro-region using near infrared light.
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
• Anterior transpetrosal approach to the prepontine epidermoids.
• Assessing health disparities in rural Hawaii using the Hoshin facilitation method.
• Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain.
• Chemical Properties and Anti-Complementary Activities of Polysaccharide Fractions from Roots and Leaves of Panax ginseng.
• Developmental transition of EEG spectra to alpha band in a sample of children with developmental disabilities.
• Effects of Exogenous Polyamines on Tropane Alkaloid Production by a Root Culture of Duboisia myoporoides.
• Flow Cytometric Analysis of Cellular Berberine Contents in High- and Low-Producing Cell Lines of Coptis japonica Obtained by Repeated Selection.
• Gas chromatography-mass spectrometric study of 19-oxygenation of the aromatase inhibitor 19-methylandrostenedione with human placental microsomes.
• High concentrations of D-amino acids in human gastric juice.
• Influences of body posture on duration of oral swallowing in normal young adults.
• Influences of thermal and gustatory characteristics on sensory and motor aspects of swallowing.
• Inhibition of tyrosine activity by cultured lichen tissues and bionts.
• Insufficiency fracture in the medial wall of the acetabulum after total hip arthroplasty.
• Lipopolysaccharide-independent limulus amebocyte lysate activating, mitogenic and anti-complementary activities of pectic polysaccharides from chinese herbs.
• Long-term grooming partnerships between unrelated adult females in a free-ranging group of Japanese monkeys (Macaca fuscata).
• Pathology of renal xenograft rejection in pig to non-human primate transplantation.
• Presumed stromal graft rejection after automated lamellar therapeutic keratoplasty: case report.
• STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells.
• Scopolamine Production in Suspension Cultures and Redifferentiated Roots of Hyoscyamus niger.
• Serial assessment of left ventricular function in various patient groups with Tl-201 gated myocardial perfusion SPECT.
• Stimulating effect of Japanese herbal (kampo) medicine, hochuekkito on upper respiratory mucosal immune system.
• The Smallest Electron Storage Ring for High-Intensity Far-Infrared and Hard X-ray Productions.
• Three-dimensional assessment of urinary stone on non-contrast helical computed tomography as the predictor of stonestreet formation after extracorporeal shock wave lithotripsy for stones smaller than 20 mm.
• Thymic rejuvenation and the induction of tolerance by adult thymic grafts.
• Transbronchial localization of small pulmonary lesions for thoracoscopic resection.
• Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer.
• [In vivo transduction of EGFP into female mouse reproductive system by electroporation and microbubble-enhanced sonoporation]